Since currently available PARG inhibitors are not satisfying so far, questioned either for their specificity or for their cell permeability [22], we evaluated the impact of PARG depletion by siRNA on cell survival of several breast and ovarian cancer cell lines either proficient or deficient in BRCA1. Here, BRCA1 is linked to ovarian cancer.